Holen Sie sich die Stockscreener-App
82.03
2.39%
-2.01
Handel nachbörslich:
82.03
Schlusskurs vom Vortag:
$84.04
Offen:
$84.13
24-Stunden-Volumen:
651.10K
Relative Volume:
0.79
Marktkapitalisierung:
$3.84B
Einnahmen:
$1.35B
Nettoeinkommen (Verlust:
$163.34M
KGV:
25.04
EPS:
3.2763
Netto-Cashflow:
$189.17M
1W Leistung:
+2.56%
1M Leistung:
-2.16%
6M Leistung:
+5.82%
1J Leistung:
+5.03%
1-Tages-Spanne:
$81.90
$84.87
1-Wochen-Bereich:
$79.41
$86.11
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
82.03 | 3.93B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics completes €185M Vivasure acquisition - BioWorld MedTech
Haemonetics acquires Vivasure Medical for EUR 100M - TipRanks
Irish medtech Vivasure sold in €185m deal to US-listed Haemonetics - Business Post
BTIG Reiterates Buy Rating for Haemonetics (HAE) at $88 Price Ta - GuruFocus
Haemonetics Expands Heart Surgery Arsenal With Vivasure Acquisition - Benzinga
Irish maker of dissolving vessel-closure implant sold in €185M deal - Stock Titan
Haemonetics (HAE) Acquires Vivasure Medical for €100M - GuruFocus
Haemonetics acquires Vivasure to expand structural heart portfolio - TipRanks
Haemonetics Acquires Vivasure Medical - Nasdaq
Haemonetics Corp Acquires Vivasure Medical Limited - TradingView — Track All Markets
New dissolving patch seals blood vessels after heart procedures - Stock Titan
Why Haemonetics Corporation stock is considered a top pick2025 Trading Recap & Fast Entry High Yield Tips - ulpravda.ru
What risks investors should watch in Haemonetics Corporation stockTreasury Yields & Comprehensive Market Scan Reports - ulpravda.ru
Why Haemonetics Corporation (HAZ) stock remains stableJuly 2025 Big Picture & Daily Profit Focused Screening - ulpravda.ru
Plasmapheresis Machines Market Outlook 2025: Expanding - openPR.com
Haemonetics sets Feb. 5 date to share its third‑quarter results - Stock Titan
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $99 - 富途牛牛
Is Haemonetics (NYSE:HAE) Using Too Much Debt? - 富途牛牛
Haemonetics Corporation (HAE) Stock Analysis: Insights into a Promising Medical Device Leader with a 9.85% Upside - DirectorsTalk Interviews
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well - simplywall.st
Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference - MarketScreener
Hear Haemonetics' CEO live at J.P. Morgan Healthcare Conference online - Stock Titan
Allspring Global Investments Holdings LLC Boosts Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (NYSE:HAE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Fort Washington Investment Advisors Inc. OH Has $34.43 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Boston Trust Walden Corp - MarketBeat
Haemonetics Corporation: The Vascular Closure Comeback Plan—Can VASCADE Reaccelerate Growth? - Smartkarma
Intuitive Surgical downgraded as Citi previews 2026 in MedTech - MSN
Harbor Capital Advisors Inc. Purchases 14,226 Shares of Haemonetics Corporation $HAE - MarketBeat
Do You Believe in the Long-Term Growth Potential of Haemonetics Corporation (HAE)? - Yahoo Finance
Aug PostEarnings: What risks investors should watch in Haemonetics Corporation stockJuly 2025 Action & AI Forecast for Swing Trade Picks - moha.gov.vn
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
Haemonetics Is Maintained at Outperform by Mizuho - 富途牛牛
Will Haemonetics Corporation stock profit from AI boomMarket Performance Report & Precise Buy Zone Identification - Улправда
Assenagon Asset Management S.A. Invests $8.56 Million in Haemonetics Corporation $HAE - MarketBeat
Is it apt to retain Haemonetics stock in your portfolio now? - MSN
Haemonetics (FRA:HAZ) EV-to-OCF : 15.32 (As of Dec. 19, 2025) - GuruFocus
Here's Why Haemonetics (HAE) is a Strong Growth Stock - Yahoo Finance
Why Haemonetics Corporation (HAZ) stock could rally stronglyWeekly Risk Summary & AI Powered Buy/Sell Recommendations - DonanımHaber
MACD Signal: Is Haemonetics Corporation stock in correction or buying zoneDollar Strength & Daily Growth Stock Investment Tips - Улправда
Haemonetics (HAE) Valuation Check After Needham Downgrade on Rising Vascular Closure Competition - simplywall.st
Haemonetics Expands Medical Solutions Across Global Healthcare - Kalkine Media
Haemonetics (NYSE:HAE) Price Target Raised to $90.00 - MarketBeat
HAE Receives Rating Update from Mizuho with Raised Price Target - GuruFocus
Haemonetics price target raised to $90 from $75 at Mizuho - TipRanks
Should Competitive Pressure In Vascular Closure Devices Prompt a Reassessment by Haemonetics (HAE) Investors? - Yahoo Finance
Riverwater Partners Small Cap Strategy Sold Its Stake in Haemonetics Corporation (HAE) in Q3 - Yahoo Finance
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 - 富途牛牛
Haemonetics (HAE) Downgraded by Needham Amid Competition Concerns - GuruFocus
Haemonetics downgraded to Hold from Buy at Needham - TipRanks
HAE: Baird Raises Price Target to $99, Rating Remains Outperform - GuruFocus
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.31%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):